EMTRICITABINE; TENOFOVIR ALAFENAMIDE

Pre-Launch

ANDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

EMTRICITABINE; TENOFOVIR ALAFENAMIDE by Aurobindo Pharma is (ftc) and tenofovir alafenamide (taf) [see ] . Approved for hiv-1 infection in pediatric patients weighing at least 14 kg to less than 35 kg in combination with other antiretroviral agents, including darunavir, cobicistat but not other protease inhibitors and 5 more indications.

Drug data last refreshed 13h ago

Mechanism of Action

(FTC) and tenofovir alafenamide (TAF) [see ] .

Indications (8)

HIV-1 infection in pediatric patients weighing at least 14 kg to less than 35 kg in combination with other antiretroviral agents including darunavir

Worked on EMTRICITABINE; TENOFOVIR ALAFENAMIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.